Contact Us
Drug Search Results
More Filters [+]

Bavituximab

Alternative Names: bavituximab
Latest Update: 2024-05-16
Latest Update Note: Clinical Trial Update

Product Description

An IgG3 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Chimeric anti-phosphotidylserine monoclonal antibody binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bavituximab)

Mechanisms of Action: Angiogenesis Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Avid Bioservices
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bavituximab

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Glioblastoma|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
STU 102017-015

P2

Active, not recruiting

Hepatocellular Carcinoma

2023-04-21

NCT03139916

P2

Completed

Glioblastoma

2022-08-31

Recent News Events

Date

Type

Title

03/11/2024

PubMed

 The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.

08/15/2023

PubMed

 Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients.

01/23/2023

News Article

 OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma

09/08/2022

News Article

 OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors

07/06/2022

News Article

 Vascular Disrupting Agents Market worth $2.25 billion by 2030 - Exclusive Report by InsightAce Analytic

06/17/2022

News Article

 Global Targeted Drug Delivery Market 2022-2030 with 2021 as the Base Year

05/21/2022

PubMed

 Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions